Castle Biosciences Presents New Data on Sentinel Lymph Node Positivity Prediction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CSTL?
Source: Newsfilter
- New Data Presentation: Castle Biosciences will present data on the DecisionDx-Melanoma's i31-SLNB test at the 2026 Society of Surgical Oncology Annual Meeting, aiming to predict sentinel lymph node positivity and further validate the test's significance in clinical decision-making.
- Clinical Validation Results: Initial study findings indicate that the test can impact sentinel lymph node biopsy decisions and identify low-risk metastatic patients, thereby optimizing patient management strategies in line with National Comprehensive Cancer Network risk thresholds.
- Personalized Risk Assessment: The i31-SLNB algorithm integrates the 31-GEP score with key clinicopathologic factors to provide a more precise risk estimation than staging alone, supporting personalized shared decision-making and enhancing patient treatment confidence.
- Broad Application Foundation: DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since launch, demonstrating its association with improved patient survival and highlighting its importance in managing cutaneous melanoma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CSTL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CSTL
Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.020
Low
41.00
Averages
47.20
High
52.00
Current: 27.020
Low
41.00
Averages
47.20
High
52.00
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Castle Biosciences Presents New Data on Sentinel Lymph Node Positivity Prediction
- New Data Presentation: Castle Biosciences will present data on the DecisionDx-Melanoma's i31-SLNB test at the 2026 Society of Surgical Oncology Annual Meeting, aiming to predict sentinel lymph node positivity and further validate the test's significance in clinical decision-making.
- Clinical Validation Results: Initial study findings indicate that the test can impact sentinel lymph node biopsy decisions and identify low-risk metastatic patients, thereby optimizing patient management strategies in line with National Comprehensive Cancer Network risk thresholds.
- Personalized Risk Assessment: The i31-SLNB algorithm integrates the 31-GEP score with key clinicopathologic factors to provide a more precise risk estimation than staging alone, supporting personalized shared decision-making and enhancing patient treatment confidence.
- Broad Application Foundation: DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since launch, demonstrating its association with improved patient survival and highlighting its importance in managing cutaneous melanoma.
See More
Castle Biosciences to Celebrate Grand Opening of New Headquarters
- New Headquarters Opening: Castle Biosciences will host a grand opening celebration for its new headquarters on March 24, 2026, marking the completion of its investment in Friendswood, with local and national officials expected to attend, highlighting the company's commitment to the community.
- Facility Features: The new 23-acre headquarters includes modern, flexible workspaces and advanced technology infrastructure designed to support the company's ongoing growth and innovation, enhancing employee experience and collaboration.
- Sustainability Focus: The building incorporates energy-efficient systems and storm-rated design elements to enhance sustainability and resilience, reflecting the company's commitment to environmental responsibility while providing amenities like a fitness center and outdoor collaboration spaces for employees.
- Community Engagement: As one of the largest publicly traded companies in Galveston County with $344 million in revenue in 2025, Castle Biosciences has a long history of supporting the Friendswood community, dedicated to improving patient lives and fostering local development.
See More
Castle Biosciences Reports Strong Q4 2025 Earnings with Revenue Growth
- Significant Revenue Growth: Castle Biosciences reported fourth-quarter revenue of $87 million and full-year revenue of $344.2 million, exceeding expectations and demonstrating sustained strong performance across core revenue drivers.
- Surge in Test Report Volume: The total test report volume from core revenue drivers increased by 37% to 105,053, with TissueCypher test report volume growing by 86%, indicating the company's strengthening competitive position in the market.
- Successful Product Launch: The AdvanceAD-Tx test saw over half of the initial 150 dermatological accounts placing orders within the first five weeks of clinical availability, with early results exceeding expectations, suggesting strong future market potential.
- Optimistic Future Outlook: Management guided total revenue for 2026 to be between $340 million and $350 million, primarily driven by continued growth in TissueCypher, reflecting the company's confidence and strategic planning for future market opportunities.
See More
Castle Biosciences to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Castle Biosciences (CSTL) is set to announce its Q4 2023 earnings on February 26 after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.26, reflecting a significant year-over-year decline of 181.3%, indicating potential profitability challenges that may affect investor sentiment.
- Revenue Forecast Changes: The revenue estimate is projected at $80.31 million, down 6.9% year-over-year; however, the company has surpassed revenue estimates 100% of the time over the past year, showcasing its resilience in the market.
- Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and no downward adjustments, while revenue estimates experienced five upward revisions and one downward, suggesting analysts' growing confidence in the company's future performance.
See More
Castle Biosciences Publishes New Study Results
- Clinical Validation Study: Castle Biosciences published a prospective multicenter clinical validation study in the Journal of the American Academy of Dermatology, demonstrating that the AdvanceAD-Tx test can identify moderate-to-severe atopic dermatitis patients who are more likely to achieve faster clinical responses when treated with JAK inhibitors, highlighting the test's significance in personalized treatment.
- Significant Efficacy Improvement: The study found that approximately 30% of patients treated with JAK inhibitors were identified as JAK Inhibitor Responders, with these patients being 5.5 times more likely to achieve at least 90% improvement in the Eczema Area and Severity Index (EASI-90) within three months compared to those treated with Th2-targeted therapies, indicating a substantial enhancement in treatment outcomes.
- Quality of Life Enhancement: Among JAK Inhibitor Responders, 45.5% reported
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Castle Biosciences Presents New Data on Sentinel Lymph Node Positivity Prediction
- New Data Presentation: Castle Biosciences will present data on the DecisionDx-Melanoma's i31-SLNB test at the 2026 Society of Surgical Oncology Annual Meeting, aiming to predict sentinel lymph node positivity and further validate the test's significance in clinical decision-making.
- Clinical Validation Results: Initial study findings indicate that the test can impact sentinel lymph node biopsy decisions and identify low-risk metastatic patients, thereby optimizing patient management strategies in line with National Comprehensive Cancer Network risk thresholds.
- Personalized Risk Assessment: The i31-SLNB algorithm integrates the 31-GEP score with key clinicopathologic factors to provide a more precise risk estimation than staging alone, supporting personalized shared decision-making and enhancing patient treatment confidence.
- Broad Application Foundation: DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since launch, demonstrating its association with improved patient survival and highlighting its importance in managing cutaneous melanoma.
See More
Castle Biosciences to Celebrate Grand Opening of New Headquarters
- New Headquarters Opening: Castle Biosciences will host a grand opening celebration for its new headquarters on March 24, 2026, marking the completion of its investment in Friendswood, with local and national officials expected to attend, highlighting the company's commitment to the community.
- Facility Features: The new 23-acre headquarters includes modern, flexible workspaces and advanced technology infrastructure designed to support the company's ongoing growth and innovation, enhancing employee experience and collaboration.
- Sustainability Focus: The building incorporates energy-efficient systems and storm-rated design elements to enhance sustainability and resilience, reflecting the company's commitment to environmental responsibility while providing amenities like a fitness center and outdoor collaboration spaces for employees.
- Community Engagement: As one of the largest publicly traded companies in Galveston County with $344 million in revenue in 2025, Castle Biosciences has a long history of supporting the Friendswood community, dedicated to improving patient lives and fostering local development.
See More
Castle Biosciences Reports Strong Q4 2025 Earnings with Revenue Growth
- Significant Revenue Growth: Castle Biosciences reported fourth-quarter revenue of $87 million and full-year revenue of $344.2 million, exceeding expectations and demonstrating sustained strong performance across core revenue drivers.
- Surge in Test Report Volume: The total test report volume from core revenue drivers increased by 37% to 105,053, with TissueCypher test report volume growing by 86%, indicating the company's strengthening competitive position in the market.
- Successful Product Launch: The AdvanceAD-Tx test saw over half of the initial 150 dermatological accounts placing orders within the first five weeks of clinical availability, with early results exceeding expectations, suggesting strong future market potential.
- Optimistic Future Outlook: Management guided total revenue for 2026 to be between $340 million and $350 million, primarily driven by continued growth in TissueCypher, reflecting the company's confidence and strategic planning for future market opportunities.
See More
Castle Biosciences to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Castle Biosciences (CSTL) is set to announce its Q4 2023 earnings on February 26 after market close, with investors keenly awaiting the results to gauge the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.26, reflecting a significant year-over-year decline of 181.3%, indicating potential profitability challenges that may affect investor sentiment.
- Revenue Forecast Changes: The revenue estimate is projected at $80.31 million, down 6.9% year-over-year; however, the company has surpassed revenue estimates 100% of the time over the past year, showcasing its resilience in the market.
- Estimate Revision Trends: Over the last three months, EPS estimates have seen four upward revisions and no downward adjustments, while revenue estimates experienced five upward revisions and one downward, suggesting analysts' growing confidence in the company's future performance.
See More
Castle Biosciences Publishes New Study Results
- Clinical Validation Study: Castle Biosciences published a prospective multicenter clinical validation study in the Journal of the American Academy of Dermatology, demonstrating that the AdvanceAD-Tx test can identify moderate-to-severe atopic dermatitis patients who are more likely to achieve faster clinical responses when treated with JAK inhibitors, highlighting the test's significance in personalized treatment.
- Significant Efficacy Improvement: The study found that approximately 30% of patients treated with JAK inhibitors were identified as JAK Inhibitor Responders, with these patients being 5.5 times more likely to achieve at least 90% improvement in the Eczema Area and Severity Index (EASI-90) within three months compared to those treated with Th2-targeted therapies, indicating a substantial enhancement in treatment outcomes.
- Quality of Life Enhancement: Among JAK Inhibitor Responders, 45.5% reported
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
